PE20210097A1 - Derivados de tetrahidrotienopiridina n-sustituidos y sus usos - Google Patents

Derivados de tetrahidrotienopiridina n-sustituidos y sus usos

Info

Publication number
PE20210097A1
PE20210097A1 PE2020002060A PE2020002060A PE20210097A1 PE 20210097 A1 PE20210097 A1 PE 20210097A1 PE 2020002060 A PE2020002060 A PE 2020002060A PE 2020002060 A PE2020002060 A PE 2020002060A PE 20210097 A1 PE20210097 A1 PE 20210097A1
Authority
PE
Peru
Prior art keywords
virus
alkyl
substituted
cyano
tetrahydrothenopyridine
Prior art date
Application number
PE2020002060A
Other languages
English (en)
Spanish (es)
Inventor
Cyrille Kounde
Wei Lin Sandra Sim
Oliver Simon
Gang Wang
Hui Quan Yeo
Bryan Ks Yeung
Fumiaki Yokokawa
Bin Zou
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67841114&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20210097(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20210097A1 publication Critical patent/PE20210097A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PE2020002060A 2018-06-19 2019-06-18 Derivados de tetrahidrotienopiridina n-sustituidos y sus usos PE20210097A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862687068P 2018-06-19 2018-06-19
PCT/IB2019/055121 WO2019244047A1 (en) 2018-06-19 2019-06-18 N-substituted tetrahydrothienopyridine derivatives and uses thereof

Publications (1)

Publication Number Publication Date
PE20210097A1 true PE20210097A1 (es) 2021-01-12

Family

ID=67841114

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020002060A PE20210097A1 (es) 2018-06-19 2019-06-18 Derivados de tetrahidrotienopiridina n-sustituidos y sus usos

Country Status (24)

Country Link
US (3) US12012417B2 (enExample)
EP (2) EP4169925B1 (enExample)
JP (1) JP7328260B2 (enExample)
KR (1) KR102835904B1 (enExample)
CN (1) CN112313237A (enExample)
AU (1) AU2019291488B2 (enExample)
BR (1) BR112020025696A2 (enExample)
CA (1) CA3100957A1 (enExample)
CL (1) CL2020003248A1 (enExample)
CR (1) CR20200618A (enExample)
CU (1) CU20200100A7 (enExample)
EA (1) EA202190046A1 (enExample)
EC (1) ECSP20080995A (enExample)
ES (2) ES3062606T3 (enExample)
IL (1) IL279441B2 (enExample)
JO (1) JOP20200326A1 (enExample)
MA (1) MA52976A (enExample)
MX (1) MX2020013852A (enExample)
MY (1) MY201990A (enExample)
PE (1) PE20210097A1 (enExample)
PH (1) PH12020552185A1 (enExample)
SA (1) SA520420809B1 (enExample)
SG (1) SG11202012625PA (enExample)
WO (1) WO2019244047A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110945002B (zh) * 2017-08-01 2021-12-24 正大天晴药业集团股份有限公司 作为RORγ抑制剂的双环化合物
AU2019291488B2 (en) 2018-06-19 2022-02-24 Novartis Ag N-substituted tetrahydrothienopyridine derivatives and uses thereof
USD1006154S1 (en) * 2023-06-27 2023-11-28 Qiongfang Mao Cable crossover attachment
WO2025238553A1 (en) 2024-05-14 2025-11-20 Novartis Ag Dosing regimens for n-(3-cyano-5-(cyclohexylmethyl)-6,6-dimethyl-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)-2-(4-sulfamoylphenyl)acetamide for use in treating or preventing a dengue virus disease or disorder
WO2025253267A1 (en) 2024-06-06 2025-12-11 Janssen Pharmaceuticals, Inc. Combination of mosnodenvir and close analogs with nitd-688 for use in the treatment and prevention of dengue disease

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807A (en) 1848-09-26 Brake fob cabs
US4656A (en) 1846-07-24 Improvement in potato-plows
US6344A (en) 1849-04-17 Driving-bobbin
US54472A (en) 1866-05-01 Improved blacking-brush
US498178A (en) 1893-05-23 William valentine leonard
US8766A (en) 1852-02-24 Appabatus for lightening vessels
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
HUP0004421A3 (en) 1996-04-23 2002-10-28 Vertex Pharmaceuticals Inc Cam Urea derivatives and pharmaceutical compositions containing them, use thereof for the treatment of deseases mediated by impdh enzyme
EP0966465B1 (en) 1997-03-14 2003-07-09 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
AP1498A (en) 1999-03-19 2005-11-21 Vertex Pharma Inhibitors of impdh enzyme.
GB0114185D0 (en) 2001-06-12 2001-08-01 Protherics Molecular Design Lt Compounds
CN1288974C (zh) 2001-05-21 2006-12-13 孟山都技术公司 含有醚胺表面活性剂的农药浓缩物
US20030232994A1 (en) 2001-10-04 2003-12-18 Shao-Po Lu Bicyclic thiophene derivatives and combinatorial libraries thereof
CA2498399A1 (en) 2002-09-12 2004-03-25 Merck & Co., Inc. Method of treating diabetes and related conditions
US7138529B2 (en) * 2003-04-16 2006-11-21 Hoffmann-La Roche Inc. Substituted 3-cyanothiophene acetamides as glucagon receptor antagonists
GB0324653D0 (en) 2003-10-22 2003-11-26 Syngenta Participations Ag Fungicides
DK1753512T3 (da) 2004-05-28 2008-11-17 4Sc Ag Tetrahydropyridothiophener
AU2005272646A1 (en) 2004-08-12 2006-02-23 Wyeth Combination therapy for diabetes, obesity, and cardiovascular diseases using GDF-8 inhibitors
AU2006212224A1 (en) 2005-02-09 2006-08-17 4Sc Ag Tetrahydropyridothiophenes for the treatment of proliferative diseases such as cancer
AU2006212179A1 (en) 2005-02-11 2006-08-17 4Sc Ag Tetrahydropyridothiophenes as antripoliferative agents for the treatment of cancer
WO2006119646A1 (en) 2005-05-13 2006-11-16 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of flavivirus infections
CA2609003A1 (en) 2005-05-25 2006-11-30 Nycomed Gmbh Tetrahydropyridothiophenes for use in the treatment of cancer
EP1893618A2 (en) 2005-05-25 2008-03-05 Nycomed GmbH Tetrahydropyridothiophenes for use in the treatment of cancer
US7932391B2 (en) 2005-09-08 2011-04-26 Zhejiang Hauhai Pharmaceutical Co., Ltd. Method for the preparation of clopidogrel and its analogues of methyl-tetrahydrothieno[3,2-C]pyridine acetate
WO2008020045A1 (en) 2006-08-16 2008-02-21 4Sc Ag Tetrahydrobenzothiophene derivatives
JP2010500395A (ja) 2006-08-16 2010-01-07 ４エスツェー アクチェンゲゼルシャフト 癌治療のためのテトラヒドロピリドチオフェン誘導体
AU2007325315A1 (en) 2006-11-28 2008-06-05 Kalypsys Inc Heterocyclic modulators of TGR5
WO2009086303A2 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
CN104856991A (zh) * 2009-02-27 2015-08-26 西佳技术公司 用于治疗和预防登革热病毒感染的噻吩并吡啶衍生物
US20130129677A1 (en) * 2009-02-27 2013-05-23 Siga Technologies, Inc. Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections
JP5701655B2 (ja) * 2011-03-29 2015-04-15 奈良県 植物精油中のトロポロン類及び／又はフェノール類の金属錯体化方法
JP2014528412A (ja) 2011-09-30 2014-10-27 キネタ・インコーポレイテツド 抗ウイルス化合物
CA3030582A1 (en) 2015-07-22 2017-01-26 The Royal Institution For The Advancement Of Learning/Mcgill University Compounds and uses thereof in the treatment of cancers and other medical conditions
CN108689987A (zh) 2017-04-05 2018-10-23 浙江海正药业股份有限公司 一种磺胺类衍生物及其制备方法和用途
UA125970C2 (uk) 2017-05-22 2022-07-20 Янссен Фармасьютікалз, Інк. Заміщені похідні індоліну як інгібітори реплікації вірусів денге
CN110945002B (zh) 2017-08-01 2021-12-24 正大天晴药业集团股份有限公司 作为RORγ抑制剂的双环化合物
CN108191885B (zh) 2018-01-29 2020-08-04 华东师范大学 一类哌啶并噻吩类小分子有机化合物及其应用
AU2019291488B2 (en) 2018-06-19 2022-02-24 Novartis Ag N-substituted tetrahydrothienopyridine derivatives and uses thereof

Also Published As

Publication number Publication date
IL279441A (en) 2021-01-31
ECSP20080995A (es) 2021-02-26
AU2019291488A1 (en) 2021-02-04
AU2019291488B2 (en) 2022-02-24
EP4169925A2 (en) 2023-04-26
US12012417B2 (en) 2024-06-18
WO2019244047A1 (en) 2019-12-26
EA202190046A1 (ru) 2021-03-24
IL279441B2 (en) 2023-06-01
SG11202012625PA (en) 2021-01-28
CU20200100A7 (es) 2021-08-06
KR102835904B1 (ko) 2025-07-22
US20260070920A1 (en) 2026-03-12
KR20210022645A (ko) 2021-03-03
ES2941946T3 (es) 2023-05-26
US20220073535A1 (en) 2022-03-10
EP3810613A1 (en) 2021-04-28
PH12020552185A1 (en) 2021-06-07
MX2020013852A (es) 2021-05-27
MY201990A (en) 2024-03-27
EP3810613B1 (en) 2023-01-11
US12331060B2 (en) 2025-06-17
EP4169925A3 (en) 2023-06-14
US20240352030A1 (en) 2024-10-24
MA52976A (fr) 2021-04-28
CA3100957A1 (en) 2019-12-26
SA520420809B1 (ar) 2022-08-17
EP4169925B1 (en) 2025-11-19
ES3062606T3 (en) 2026-04-13
CN112313237A (zh) 2021-02-02
CL2020003248A1 (es) 2021-07-09
CR20200618A (es) 2021-01-21
JP7328260B2 (ja) 2023-08-16
JOP20200326A1 (ar) 2020-12-14
JP2021529159A (ja) 2021-10-28
BR112020025696A2 (pt) 2021-03-16

Similar Documents

Publication Publication Date Title
PE20210097A1 (es) Derivados de tetrahidrotienopiridina n-sustituidos y sus usos
PE20171341A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas
AR053652A1 (es) Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas
AR078152A1 (es) Compuestos heterociclicos, utiles para el tratamiento de hcv y composiciones farmaceuticas que los comprenden
AR043700A1 (es) Derivados de 3-substituida-4-pirimidona
HUP0401784A2 (hu) Heterobiciklikus szerkezetû virális polimeráz inhibitorok, eljárás az elõállításukra, köztitermékek és ezeket tartalmazó gyógyszerkészítmények
AR114793A1 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de los mismos
AR106037A1 (es) Moduladores de la proteína core de la hepatitis b
AR065439A1 (es) Derivados de tiazoles 1,3 no condensados,composiciones farmaceuticas que los contienen y usos como agentes antivirales, en particular anti hiv.
AR059338A1 (es) N-fenilbenzotriazolilo como inhibidores de c-kit
AR075510A1 (es) Inhibidores del virus de la hepatitis c
AR054612A1 (es) Derivados de espiroquetas y composiciones farmaceuticas para su utilizacion como agente terapeutico para diabetes
PE20140522A1 (es) Derivados de nucleosidos 2'- sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
PE20140302A1 (es) Inhibidores del virus de la hepatitis c
AR079634A1 (es) Inhibidores del virus de la hepatitis c
AR049092A1 (es) Derivados de tetrahidronaftiridina como ligandos del receptor h3 de histamina
PE20130281A1 (es) Derivados de acido 5-alquinil-3-amida-2-tiofeno-carboxilico como inhibidores del virus flaviviridae
AR053195A1 (es) Compuestos inhibidores de dipeptidil peptidasa-iv metodos para preparar los mismos y composiciones farmaceuticas que los contienen como un agente activo
AR090760A1 (es) Compuestos de benzotiazol y su uso contra el virus de hiv
AR076274A1 (es) Inhibidores del virus de la hepatitis c
AR066669A1 (es) Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas.
AR072726A1 (es) Derivados de indol macrociclicos utiles como inhibidores del virus de la hepatitis c
PE20220252A1 (es) Compuestos de pirrol
AR059886A1 (es) Derivados de amidas como inhibidores de renina
AR069813A1 (es) Derivados de 2- amino-pirimidina, una composicion farmaceutica, un metodo de preparacion del compuesto y uso del mismo para preparar un medicamento